January 31, 2018 / 1:44 PM / Updated 9 minutes ago BRIEF-Dermira Initiates Mid-Stage Study Testing Eczema Treatment Reuters Staff 
Jan 31 (Reuters) - Dermira Inc: 
* DERMIRA INITIATES PHASE 2B DOSE-RANGING STUDY EVALUATING LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS 
* DERMIRA INC - ‍TOPLINE RESULTS FROM PHASE 2B DOSE-RANGING STUDY​ EXPECTED IN FIRST HALF OF 2019 Source text for Eikon: Further company coverage: